(Q38153607)

29 August 2017

title

Fidaxomicin: a review of its use in patients with Clostridium difficile infection (English)

1 reference

29 August 2017

main subject

Clostridium difficile

0 references

1

Lesley J Scott

1 reference

29 August 2017

language of work or name

1 reference

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

73

1 reference

29 August 2017

issue

15

1 reference

29 August 2017

page(s)

1733-1747

1 reference

Fidaxomicin: a new option for the treatment of Clostridium difficile infection

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Comparative effectiveness of Clostridium difficile treatments: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Clostridium difficile infection: new insights into management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

In vitro activity of OPT-80 against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Fidaxomicin inhibits spore production in Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Fidaxomicin inhibits toxin production in Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Antimicrobial activities of fidaxomicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Effect of age on treatment outcomes in Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Is fidaxomicin worth the cost? An economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

Recurrent Clostridium difficile infection: what are the treatment options?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0134-Z

The search for effective treatment of Clostridium difficile infection

21 January 2018

1 reference

12 December 2020

Fidaxomicin: in Clostridium difficile infection

1 reference

12 December 2020

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

1 reference

12 December 2020

Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

1 reference

12 December 2020

Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.40.567

Identifiers

DOI

10.1007/S40265-013-0134-Z

1 reference

Dimensions Publication ID

29 August 2017

1017185434

0 references

1 reference